Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”) today announces that it has commenced supplying Oseltamivir capsules, Oseflu® (BPL′s generic version of Tamiflu® ), to Latin and Central American countries, the regions most affected by the recent H1N1 swine flu (influenza A) outbreak.
In a meeting of the Board of Directors of Beximco Pharmaceuticals Ltd (“BPL” or the “Company”) held on 7th May 2009 Mr. Nazmul Hassan was appointed Managing Director of the Company.
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter from Bangladesh, announces the achievement of a milestone today following the receipt of approval from the Ministry of Health of Gulf Cooperation Council (GCC) countries for BPL to commence export of medicines into the GCC. BPL is the first company from Bangladesh to receive this approval.
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has commenced exports to Chile, after receiving marketing authorization for a number of products from “Instituto de Salud Publica de Chile” (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country, a company statement said today.
Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi pharmaceutical manufacturer and exporter, is pleased to announce that it has received approval (GMP Clearance) from Therapeutic Goods Administration (TGA), Australia for its new Oral Solid Dosage (Tablet, Capsule), and the Metered Dose Inhaler and Spray manufacturing facilities. BPL is the first Bangladeshi company to receive this regulatory approval from TGA, Australia through a stringent facility audit process.
Leading drug manufacturer in Bangladesh Beximco Pharmaceuticals Limited introduced yesterday (March 22, 2006) Oseflu capsule for the prevention and treatment of human cases of Avian influenza (H5N1) causing Bird flu.
Dhaka, March 13, 2006: Taking advantage of the exemptions of ‘Pharmaceutical Product patent’ for the Least Developed Countries (LDCs) until 2016, as given by the Doha Declaration of Trade Related aspects of Intellectual Property rights (TRIPs), Beximco Pharmaceuticals participated in the three-day ‘Pharmaceutical Product Show’ in Myanmar with a massive market expansion plan.
Sri Lanka plans to import more drug items from country’s leading drug manufacturer Beximco Pharmaceuticals Limited (BPL).